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Abstract Depression carries serious psychosocial, physi-
cal, and economic consequences for cancer survivors. Study
goals were to characterize patterns and predictors of depres-
sive symptoms and major depressive episodes in recently
diagnosed breast cancer patients. Consecutively recruited
women (N = 460) completed a validated interview (CIDI)
and questionnaire measure (CES-D) of depression within
4 months after invasive breast cancer diagnosis and at six
additional assessments across 12 months. Outcomes were
major depressive episodes, continuous symptom scores, and
latent symptom trajectory classes. Across 12 months, 16.6 %
of women met criteria for a major depressive episode.
Unemployment predicted depressive episodes after other
correlates were controlled. Distinct trajectory classes were
apparent: an estimated 38 % of women had chronically ele-
vated symptoms (High trajectory), 20 % recovered from
elevated symptoms (Recovery), and 43 % had lower symp-
toms (Low and Very Low trajectories). Although 96 % of
episodes occurred in the High or Recovery classes, 66 % of
women in theHigh trajectory did not have an episode.Women
in the Low (vs High) trajectory were more likely to be older,
retired, more affluent, and have fewer comorbid diseases and
briefer oncologic treatment. Women in the Recovery trajec-
tory (vs High) were more likely to be married and more
affluent and have fewer comorbid diseases. Assuming avail-
able therapeutic resources, assessment of both depressive
symptoms and episodes over several months after diagnosis is
important. Identification of patients at risk for persistently
high depressive symptoms (e.g., younger, longer treatment
course) opens targeted opportunities to prevent and promote
rapid recovery from depression.
Keywords Breast cancer  Depression  Survivorship 
Trajectory
Although transient depressed mood constitutes an expected
result of the cancer experience, prolonged or severe
depressive symptoms confer risk for profound psychoso-
cial, physical, and economic impact. Depression in cancer
survivors not only is painful in itself, but also delays return
to work [1], predicts lower adherence to medical regimens
and engagement in health-promoting behaviors [2–4], and
prompts higher healthcare utilization and costs, as well as
depression-associated hospitalizations [5, 6]. The risk of
suicide is elevated in cancer survivors versus the general
population [7, 8]. Depression also may confer risk for
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mortality in cancer [9–11], a relationship for which plau-
sible biological mediators exist [12]. In particular,
unremitting (vs transient) depressive symptoms predict
lower survival from chronic diseases, including cancer
[13–15].
Potentially meaningful differences in the contributors to
and consequences of depressive symptoms as a function of
their intensity and duration render it essential to study
depression over time in cancer patients and to identify
predictive factors. Accordingly, a goal of this research was
to characterize major depressive episodes and symptoms in
a sample of women with breast cancer during the first
16 months after diagnosis. A second goal was to identify
sociodemographic and medical markers of risk for the three
primary endpoints: depressive episodes, depressive symp-
toms, and symptom trajectories.
Prospective studies demonstrate that depressive symp-
toms increase after a breast cancer diagnosis, with the
highest burden during the first 6 months relative to pre-
diagnosis levels [16]. A meta-analysis of interview-diag-
nosed major depression in cancer survivors in non-pallia-
tive care settings demonstrated a 16.3 % point prevalence
of major depression (95 % CI 13.4–19.5; 14.1 % in breast
cancer patients) [17]. Research documenting trajectories of
depressive symptoms after diagnosis suggests that a
minority has persistently high depressive symptoms,
another group recovers from elevated symptoms over the
first several months, and a sizeable proportion of cancer
patients report low depressive symptoms from the point of
cancer diagnosis onward [18–20]. Elevated distress during
the re-entry phase after treatment completion can occur in a
minority of cancer survivors [18, 21].
Relatively few studies involve assessment of depression
at multiple points with both validated diagnostic interview
and questionnaire methods, which is a primary goal of this
study. Moreover, the concordance of major depressive
episodes and symptom trajectories is unexplored and is
important in its potential to reveal whether each charac-
terization offers distinct information regarding survivors at
risk. In addition to hypothesizing elevated symptoms and
depressive episodes in women with recently diagnosed
breast cancer relative to the comparable general popula-
tion, we anticipated considerable overlap between the
presence of depressive episodes and trajectory classes
reflecting chronically high or recovering symptom trajec-
tories. We explored whether the two approaches yielded
unique information of potential clinical value.
Early identification of vulnerable cancer survivors is
vitally important for preventive and intervention efforts.
Accordingly, another goal was to examine the associated
sociodemographic and medical factors that can be easily
and routinely assessed in the oncologic setting. We
hypothesized that younger age [18, 19, 22–26] and markers
of socioeconomic disadvantage [18, 19, 23, 24, 26] would
be associated with depression endpoints and explored other
sociodemographic and medical factors [18–20, 23, 24, 27].
Patients and method
Patients
Participants were 460 women diagnosed with invasive
breast cancer during the prior 4 months at three oncology
clinics in the greater Los Angeles area and at the University
of Arizona Cancer Center (Tucson). Of 823 women
approached (n = 406 Arizona, n = 417 California), 61
were ineligible upon screening (8 %; n = 46 Arizona,
n = 17 California). Of the 762 eligible women, 302 (40 %;
n = 198 Arizona, n = 104 California) declined or were
unreachable by telephone, and 460 (60 %; n = 163 Ari-
zona, n = 297 California) consented and took part in the
study entry assessment. Of the 460 participants, 428, 420,
411, and 411 completed assessments at Week 6, 12, 18, and
24, respectively. At 9 and 12 months, 390 and 372 com-
pleted assessments, respectively, yielding 81 % retention at
12 months.
Procedures
The University of California, Los Angeles, and University
of Arizona institutional review boards approved research
procedures. Research or clinic staff identified consecutive
(within scheduling constraints), potentially eligible patients
via medical records. Research staff introduced the study in
person as designed to examine ‘‘women’s emotional and
physical experiences during and after treatment for breast
cancer.’’ Eligibility criteria were as follows: new diagnosis
or first recurrence/second primary of invasive breast cancer
(Stage 1–4), study entry session within 4 months following
cancer diagnosis, and English literacy. Any standard
medical treatment for cancer was allowed, as was addi-
tional medication. Exclusion criteria were as follows:
younger than 21 years and current or past bipolar disorder,
schizophrenia, and schizoaffective or neurocognitive dis-
order (e.g., dementia).
Study entry and 9-month in-person assessments
The first assessment, lasting approximately 3 h, was com-
pleted in a private room at the treating clinic or women’s
homes by post-baccalaureate research staff. After provid-
ing informed consent, participants completed self-report
measures (and additional assessments not included here)
via interview or computer-aided as facilitated by staff
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(based on preference). The 1-h, 9-month assessment used
the same procedure.
Telephone assessments
Frequent assessments were conducted to ensure docu-
mentation of major depressive episodes during the inten-
sive medical treatment phase. Every 6 weeks for 6 months
after study entry, as well as at 12 months, participants
completed a 30-min phone assessment. Women received
$60 compensation for in-person and $30 for phone
assessments.
Measures
Sociodemographic and medical variables
Age, marital status, race/ethnicity, education, employment,
yearly family income, subjective social status [28], number
of comorbid physical diseases [29], and study recruitment
site were self-reported at study entry.
Cancer stage, primary or recurrent diagnosis, and diag-
nosis date were obtained via medical record review, sup-
plemented by self-report when the record was unavailable
(n = 39). Other self-reported variables (confirmed through
medical records) at each assessment were surgery,
chemotherapy, radiotherapy, endocrine therapy, Herceptin,
and oncologic treatment duration (the assessment point at
which primary oncologic treatments were completed).
At each assessment, self-reported receipt of psycholog-
ical or pharmacologic (confirmed through medical records)
treatment of depression was assessed. Treatment was coded
for minimal adequacy from evidence-based guidelines of
receiving C2 months of an appropriate medication or C8
visits with a mental health professional averaging C30 min
each [30].
Major depressive episodes and symptoms
At all assessments, trained and supervised research staff
administered modules of the structured, computer-guided
Composite International Diagnostic Interview (CIDI) [31,
32] to assess major depressive episodes, a primary end-
point. Two authors (ALS and KLW) reviewed CIDI data to
ensure that any episode did not reflect solely the neu-
rovegetative symptoms that can accompany cancer treat-
ments [33].
At all assessments, participants completed the Center for
Epidemiologic Studies-Depression scale (CES-D) [34].
The two major endpoints were continuously scored CES-D
depressive symptoms and CES-D symptom trajectory
classes. CES-D scores C16, the clinically suggestive
threshold [35], also are reported.
Data analysis
Descriptive statistics were calculated on all variables. We
examined variables related to missing data using a struc-
tural equation modeling framework in which the two out-
comes were study dropout (months after diagnosis when
dropout occurred), using a Cox proportional hazards model
[36], and intermittent missingness, using an intercept-only
logistic latent growth model.
Based on research on symptom trajectories in breast
cancer patients [21, 37] and model complexity, we tested
one- to five-class CES-D symptom trajectories using finite
Gaussian mixture models [38] with latent growth curve
modeling [39], using continuous months since cancer
diagnosis and allowing for random linear and quadratic
time trends. Each woman was assigned to one class based
on highest individual probabilities.
Sociodemographic and medical variables were assessed
as correlates of major depressive episodes (using logistic
regression), continuous CES-D symptoms (using multilevel
structural equation modeling), and CES-D depressive
symptom trajectory classes (using multinomial logistic
regression). Each correlate was entered individually and
multivariately with all others.
Data were analyzed using R v. 3.1.3 [40] and Mplus v.
7.3 [41] via MplusAutomation v. 0.6-3 [42]. Full-infor-
mation maximum likelihood was used to address missing
data in all models [43]. The robust maximum likelihood
estimator was used to provide model fit and standard errors
robust to non-normality, and Chi-square difference tests
(e.g., for evaluating the overall significance of a variable in
the multinomial models for trajectory class) used the
scaling correction factor [44].
Results
Sample characteristics
Table 1 contains sociodemographic and medical charac-
teristics. Most women were college educated, married/liv-
ing as married, and employed. Most had early-stage breast
cancer and surgery, chemotherapy, and endocrine therapy
during the study.
Missing data and study dropout
Of 460 participants, 63 (13.7 %) had intermittent missing
data and 88 (19 %; n = 9 deaths) dropped out of the
12-month assessment. Missingness and dropout were not
related significantly to major depressive episodes or CES-D
symptoms. Higher rates of intermittent missing data were
associated significantly with higher income and California
Breast Cancer Res Treat (2015) 154:105–115 107
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Table 1 Demographic and
medical characteristics of
recently diagnosed breast cancer
patients (N = 460)
Characteristic n (%)
Age, mean (SD; range) years 56.4 (12.6; 23–91)
Ethnicity
Asian 24 (5.2)
Black/African American 10 (2.2)
Latina 89 (19.3)
Mixed race/ethnicity 8 (1.7)
Native American/Alaska Native 12 (2.6)
Native Hawaiian/Pacific Islander 3 (0.7)
Unreported 3 (0.7)
White/European American 311 (67.6)
Marital status
Married/living as married 305 (67.0)
Single 42 (9.2)
Divorced/separated 72 (15.9)
Widowed 36 (7.9)
Incomea
\$50,000 124 (28.5)
$50,000–$74,999 97 (22.3)
$75,000–$100,000 57 (13.1)
[$100,000 157 (36.1)
Educationa
\High school 18 (4.0)
High school 96 (21.1)
Two-year college 91 (20.0)
College graduate 164 (36.1)
Master’s degree 62 (13.7)
Ph.D., M.D., other professional terminal degree 23 (5.1)
Employment status
Employed 236 (52.1)
Retired 134 (29.6)
Unemployed 83 (18.3)
Subjective SES, mean (SD) 6.98 (1.56)
Recruitment site
Arizona 163 (35.4)
California 297 (64.6)
Number of comorbidities, mean (SD) 1.8 (1.9)
Cancer stage
1 204 (44.4)
2 178 (38.8)
3 52 (11.3)
4 25 (5.4)
Cancer status
Primary non-metastatic 387 (84.3)
Recurrence/2nd primary 47 (10.2)
Primary metastatic 14 (3.1)
Metastatic recurrence 11 (2.4)
Months since diagnosis at study entry, mean (SD) 2.1 (0.8)
Oncologic treatment duration, mean (SD)b 3.5 (2.0)
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recruitment (vs Arizona) (see online supplement). More
advanced cancer and California recruitment predicted
earlier study dropout (see online supplement). Study
dropout also was related significantly to cancer treatment
variables, but interpretation is complicated by the fact that
women who dropped out earlier necessarily had a shorter
follow-up period and were thus less likely to be observed to
have a specific treatment or long-duration treatment.
Characterization of depressive episodes, symptoms,
and trajectories
Table 2 displays major depressive episodes and mean
CES-D total scores in three-month intervals. Across the
study period, 16.6 % of women met CIDI criteria for a
major depressive episode, and 56.5 % met the CES-D
cutoff of 16. Depressive symptom elevation and episodes
were most likely to occur within 9 months of diagnosis.
The estimated overall mean of CES-D scores indicates
declining depressive symptoms over the 16 months
(Fig. 1).
We selected the final four-class CES-D symptom tra-
jectory model (Table 3) based on the best fit indices from
the one- to four-class latent growth curve modeling solu-
tions (five-class solution was unstable), yielding High,
Recovery, Low, and Very Low depressive symptom tra-
jectory classes. Entropy was acceptable (0.81), indicating
that women could be classified into one specific class with
Table 1 continued
Characteristic n (%)
Oncologic treatments received
Chemotherapy 242 (53.0)
Radiation therapy 170 (37.2)
Surgery 414 (90.6)
Herceptin 128 (28.0)
Aromatase inhibitor/endocrine antagonist 293 (64.1)
SES Socioeconomic status
a For analysis, variables coded numerically starting from zero (total yearly income and years of education,
respectively)
b Assessment interval (1–7) at which major oncologic treatments (surgery, chemotherapy, radiation) ended.
Mean of 3.5 (2.0) = 6.38 ± 3.78 months after diagnosis
Table 2 Cross-classification of major depressive episode and CES-D symptom trajectory class with depression treatment and time since breast
cancer diagnosis
Major depressive episode CES-D trajectory class
Very Low Low Recovery High
No 48 (100.0 %) 142 (97.9 %) 76 (84.4 %) 115 (66.1 %)
Yes 0 (0.0 %) 3 (2.1 %) 14 (15.6 %) 59 (33.9 %)
Depression Treatment No. (%) No Yes
Adequate 45 (11.8 %) 26 (34.2 %) 0 (0.0 %) 20 (13.8 %) 6 (6.7 %) 45 (25.9 %)
Inadequate/Indeterminate 47 (12.3 %) 16 (21.1 %) 3 (6.2 %) 8 (5.5 %) 18 (20.0 %) 34 (19.5 %)
None 290 (75.9 %) 34 (44.7 %) 45 (93.8 %) 117 (80.7 %) 66 (73.3 %) 95 (54.6 %)
Months since diagnosis Major depressive episode CES-D mean (SD) CES-D C 16a
0 to\3 20 (4.4 %) 12.55 (10.34) 134 (33.0 %)
C3 to\6 21 (4.9 %) 11.99 (9.92) 169 (38.5 %)
C6 to\9 20 (5.1 %) 10.23 (9.47) 122 (29.2 %)
C9 to\12 10 (2.8 %) 8.15 (9.43) 56 (17.6 %)
C12 to last assessmentb 5 (1.6 %) 7.25 (8.43) 59 (15.6 %)
Total unique cases across time 76 (16.6 %) – 260 (56.5 %)
Results are number (percentage) unless otherwise noted. For cross-classification, percentages are for columns. For depression over time,
percentages are for number with a depressive episode or CES-D C 16 versus not. CES-D Center for Epidemiologic Studies-Depression scale
a Scores C16 on the CES-D are suggestive of clinically relevant depressive symptoms (35)
b Last assessment ranged from 12 to 19 months since diagnosis, with a mean of 14.1 months
Breast Cancer Res Treat (2015) 154:105–115 109
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high probability. Mean trajectories and the proportion of
women in each class are shown in Fig. 1.
Table 2 cross-classifies participants on major depressive
episodes and CES-D trajectories. Depressive episodes
occurred almost solely in the High or Recovery trajectory
classes (96 % of 76 episodes), with rates of 34 %, 16 %,
2 %, and 0 depressive episodes in the High, Recovery,
Low, and Very Low trajectory classes, respectively.
However, 66 % of the estimated membership of the High
trajectory class did not have a major depressive episode.
Sociodemographic and medical correlates
of depression
Table 4 displays correlates of major depressive episodes
and CES-D symptoms. Table 5 displays correlates of CES-
D trajectory classes. As hypothesized, socioeconomic
disadvantage and younger age were consistently associated
with less favorable outcomes as indicated by higher like-
lihood of a major depressive episode (except younger age),
higher depressive symptoms, and less favorable depressive
symptom trajectories. Within socioeconomic indicators,
retirement or higher perceived socioeconomic status was
associated with more favorable status on the three end-
points, and unemployment (versus employment) was
associated significantly with major depressive episodes and
continuous CES-D. Being married or living as married also
indicated advantage on the three outcomes, as did being
recruited in Arizona. Being Latina (versus other ethnicity/
race) evidenced largely non-significant relations with
depression indicators.
Regarding medical factors, less favorable CES-D
symptom trajectories occurred with more comorbid dis-
eases. CES-D depressive symptoms and less favorable
trajectory class increased with cancer stage. With regard to
major depression (see online supplement), no woman with
metastatic cancer (n = 25), either primary or recurrent, had
an episode. Women with primary non-metastatic cancer
had the highest likelihood of major depressive episodes
(18.7 %; 72/385), followed by local recurrence/second
primary (8.5 %; 4/47).
Longer oncologic treatment duration was related to
higher depression on the three endpoints. Patterns for the
specific cancer treatments were more complex. Having
surgery or chemotherapy shortly after diagnosis was
associated with lower CES-D scores, but a slower CES-D
decline across time. Having radiation therapy early was
associated with a faster decline in CES-D. Having endo-
crine therapy early was associated with lower CES-D.
Women who had a depressive episode were more likely
to receive adequate (OR = 4.93, P\ 0.001) or inadequate/
All (N = 457)
Low (32%)
High (38%)
Recovery (20%)
Very Low (11%)
0
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Fig. 1 Depressive symptom
trajectories: overall mean CES-
D trajectory and mean CES-D
trajectories of the four classes
identified through latent growth
mixture modeling
Table 3 Fit indices from latent growth mixture models to identify
depressive symptom (CES-D) trajectory classes
1 Class 2 Class 3 Class 4 Class
Parameters 16 33 50 67
LL -9641.23 -9144.75 -8989.19 -8915.16
AIC 19,314.46 18,355.49 18,078.39 17,964.32
BIC 19,380.46 18,491.61 18,284.62 18,240.68
aBIC 19,329.68 18,386.88 18,125.94 18,028.04
AICC 19,315.7 18,360.8 18,090.95 17,987.75
Entropy 1.00 0.86 0.87 0.81
N = 457 for all models. CES-D Center for Epidemiologic Studies-
Depression Scale, LL log likelihood, AIC Akaike Information Crite-
rion, BIC Bayesian information criterion, aBIC adjusted Bayesian
information criterion, AICC Akaike Information Criterion with sam-
ple size correction
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indeterminate (OR = 2.90, P = 0.002) depression treat-
ment (Table 2). Only 34.2 % with a depressive episode and
25.9 % in the High CES-D trajectory class had adequate
treatment, however.
Discussion
This longitudinal study of 460 women with breast cancer
diagnosed an average of 2 months previously yielded a
16.6 % rate of major depressive episodes over 12 months,
as assessed via validated structured interview. This figure is
nearly twice the 8.4 % 12-month prevalence in women in
the general United States population [45]. Compared with a
CES-D mean of 8.67 in community-residing women aged
50–96 years [35], depressive symptoms were elevated up
to the ninth month after breast cancer diagnosis, but not
thereafter. Similarly, the proportion of participants who
met the clinically suggestive CES-D cutoff at some point in
the 12 months (56.5 %) exceeded the 15 % 12-month rate
in a community sample [35].
Depressive symptoms declined over time, but substan-
tial heterogeneity was apparent, as indicated by four dis-
tinct symptom trajectory classes. The trajectory classes
identified in the current study correspond to those of other
studies. For example, although depressive symptoms were
higher in the current sample, our High trajectory class
(38 % of participants) roughly corresponds to the 45 % of
398 breast cancer patients with estimated CES-D scores of
just above 16 through 6 months after surgery [18]. Con-
sidered jointly, our Low and Very Low classes (43 %)
correspond to 39 % with consistently low depressive
Table 4 Univariate associations of demographic and medical covariates with major depressive episodes (MDE) and continuous CES-D
depressive symptoms
Covariate Odds ratio for MDE Univariate coefficients in mixed models of CES-D depressive symptoms
Intercept Linear slope Quadratic slope
Age (in years) 0.99 [0.97, 1.00] -0.22*** [-0.32, -0.12] 0.01 [-0.01, 0.04] 0.00 [-0.00, 0.00]
Latina (ref = non-Latina) 1.18 [0.64, 2.16] 2.27 [-1.05, 5.59] -0.33 [-1.15, 0.49] 0.02 [-0.03, 0.06]
Married (ref = non-married) 0.56* [0.33, 0.93] -3.75* [-6.68, -0.83] 0.29 [-0.38, 0.96] -0.02 [-0.05, 0.02]
Income 0.92 [0.75, 1.13] 0.34 [-0.71, 1.40] -0.18 [-0.42, 0.06] 0.01 [-0.00, 0.02]
Education 0.99 [0.82, 1.20] -0.34 [-1.39, 0.70] 0.10 [-0.14, 0.33] -0.00 [-0.02, 0.01]
Employment (ref = employed)
Retired 0.54 [0.28, 1.05] -6.44*** [-9.10, -3.78] 0.61 [-0.02, 1.24] -0.02 [-0.06, 0.01]
Unemployed 1.93* [1.07, 3.48] 4.43* [0.68, 8.17] -0.02 [-0.86, 0.82] -0.01 [-0.05, 0.04]
Subjective SES 0.80** [0.67, 0.95] -1.32** [-2.26, -0.39] 0.01 [-0.20, 0.23] 0.00 [-0.01, 0.01]
Cancer stage 0.85 [0.64, 1.11] 1.64* [0.16, 3.11] -0.20 [-0.54, 0.13] 0.01 [20.01, 0.03]
Oncologic treatment durationa 1.19** [1.04, 1.35] 0.88** [0.26, 1.50] 0.02 [-0.12, 0.16] -0.00 [-0.01, 0.00]
Surgery 1.57 [0.60, 4.14] -2.78* [-4.93, -0.63] 1.04** [0.34, 1.75] -0.06* [-0.10, -0.01]
Chemotherapy 1.27 [0.77, 2.09] -1.74 [-4.36, 0.88] 1.02* [0.14, 1.89] -0.07* [-0.12, -0.01]
Radiation therapy 0.92 [0.55, 1.53] 1.95 [-1.59, 5.49] -1.21* [-2.25, -0.16] 0.10** [0.03, 0.18]
Herceptin 0.98 [0.56, 1.70] 0.10 [-2.61, 2.81] 0.39 [-0.32, 1.09] -0.03 [-0.07, 0.01]
Comorbidities 1.04 [0.92, 1.18] -0.35 [-1.08, 0.38] 0.07 [-0.09, 0.23] -0.00 [-0.01, 0.01]
AI/EA therapy 0.64 [0.39, 1.05] -1.69* [-3.31, -0.08] 0.11 [-0.22, 0.44] -0.01 [-0.03, 0.01]
Recruitment site (CA vs. AZ) 1.97* [1.12, 3.48] 2.80* [0.23, 5.37] -0.00 [-0.58, 0.57] 0.00 [-0.03, 0.03]
* Indicates statistical significance in the univariate tests, and bolded values indicate significance (p\ 0.05) in the multivariate model (see online
supplement for coefficients from the multivariate models). Cancer status (e.g., primary, recurrent) not included in analyses, owing to small
subsample sizes. For major depressive episodes, surgery, chemotherapy, radiation therapy, Herceptin, and endocrine therapy are indicators of
receipt during the study. In the mixed models, oncologic treatments are time-varying, within-subject factors. For all estimates, 95 % confidence
intervals are shown in brackets
a Assessment interval (1–7) at which major oncologic treatments (surgery, chemotherapy, radiation) ended
CES-D Center for Epidemiologic Studies-Depression scale, AI aromatase inhibitors, EA endocrine antagonists, CA California (Los Angeles area),
AZ Arizona (Tucson)
* P\ 0.05
** P\ 0.01
*** P\ 0.001
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symptoms [18]. As did 20 % of the current sample,
15–25 % of cancer patients and other adults experiencing
major life stressors demonstrate a recovery trajectory [21,
46]. No re-entry trajectory was apparent (including when
analyses were conducted specifically to examine symptom
patterns after treatment completion [data not shown]).
Regarding cross-classification of the depression indica-
tors, the High and Recovery classes contained 96 % of the
major depressive episodes. As previously demonstrated
[47], many women with clinically significant levels of
depressive symptoms (C16 CES-D) did not meet criteria
for a major depressive episode. The fact that an estimated
66 % of women in the High symptom class did not have a
depressive episode reveals a need for clinical attention to
women who report persistently elevated depressive symp-
toms, as well as indicating the unique value of repeated
symptom assessments even in the absence of formal
diagnostic evaluation.
The three depression indicators generally had similar
correlates. Exceptions were that younger (vs older) age and
advanced (vs early) cancer stage were significantly asso-
ciated with chronically elevated depressive symptoms, but
not with episodes (no woman with metastatic disease had
an episode). In that they face attendant enduring and major
life changes, perhaps younger women and women with
metastatic disease are more likely to experience persistent
(but subthreshold) depressive symptoms. No other predic-
tor uniquely distinguished women who had a major
depressive episode from those who reported relatively high
and chronic symptoms. Both patterns are of clinical
concern.
The trajectory class findings are useful in distinguishing
women whose elevated depressive symptoms are likely to
endure and warrant intervention versus those who recover
in their natural environments. Compared to women who
recovered from elevated symptoms, women with high and
persistent depressive symptoms were significantly more
likely to be younger, of lower perceived socioeconomic
status, unmarried, diagnosed with comorbid diseases, and
recruited from the Los Angeles area. Unemployment
increased the likelihood of major depressive episodes, after
accounting for other medical and sociodemographic fac-
tors. These significant correlates also are related to
depression in the general population [48, 49], and it cer-
tainly is likely that some women in the High trajectory
were depressed prior to cancer diagnosis. A recent
prospective study demonstrated that an estimated 8 % of
the sample reported high depressive symptoms prior to a
cancer diagnosis, which endured after diagnosis [50].
Regarding limitations on generalizability of findings, the
sample was younger (mean of 56 ± 13) than the median
age of breast cancer diagnosis of 61 years [51]; a some-
what lower rate of depressive symptoms might be evident
in older samples. African American women were under-
represented and Latinas over-represented relative to the US
population with breast cancer (although representative of
the local recruitment populations). Regarding recruitment
site differences, competition for recruitment at Arizona’s
academic site versus California’s primarily community
sites likely accounts for Arizona’s lower recruitment rate.
California’s higher attrition and depressive symptom rates
are less explicable. Women with advanced cancer also
were more likely to drop out of the study; however, total
retention at 12 months exceeded 80 %, analyses addressed
missing data, and attrition was not affected by depression
status.
In light of the profound consequences of depression for
the well-being and health of cancer survivors [5, 9], this
novel simultaneous examination of major depressive epi-
sodes, depressive symptoms, and trajectory classes via
multiple assessments across 12 months suggests the
importance of assessing both major depressive episodes
and unremitting depressive symptoms. It is heartening that
several factors significantly associated with enduring (vs
remitting or low) depressive symptoms can be assessed
upon cancer diagnosis, and identification of additional
factors that confer risk for major depression or prolonged
symptoms warrants investigation. Psychosocial predictors
of depressive symptoms also are documented in breast
cancer survivors [e.g., 18, 22], and planned analyses will
illuminate psychosocial processes indicating vulnerability
or protection in the present sample of women. Whether
interventions with distinct content or intensity are needed
for disorder-level versus persistent subthreshold symptoms
requires study.
The present and others’ findings suggest that nearly
40 % of recently diagnosed breast cancer patients might
need targeted intervention to prevent unremitting depres-
sive symptoms, approximately 20 % could benefit from
approaches to speed recovery, and 40 % are likely to
garner sufficient resources in their natural environments.
Nearly half of participants with major depressive disorder
received no depression treatment, illustrating the impor-
tance of improving detection and treatment of depression.
Psychological and pharmacologic approaches show pro-
mise in ameliorating major depression in cancer survivors
[52, 53], and continued development of evidence-based
interventions is needed to prevent and promote rapid
recovery from depression.
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